H.R. 2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act

117th Congress

To amend title 35, United States Code, to clarify and improve the process for subsection (k) applicants to resolve patent infringement claims for biological products (commonly known as the

Sponsor: Rep. Henry Johnson — D — GA

Limits in certain instances the number of patents that the manufacturer of a biologic drug can assert in a lawsuit against a company seeking to sell a biosimilar version of that drug. (A biologic drug is produced through natural processes or isolated from natural sources. A biosimilar version is substantially similar to the original biologic, which is the reference product, and is often marketed as a...

View the full vote history of this bill on GovTrack.us.